Slightly increased risk of meningioma with certain contraceptives containing desogestrel and etonogestrel
Imported from official source
In July 2026, the Pharmacovigilance Risk Assessment Committee (PRAC) recommended adding the risk of meningioma to the package leaflet and to the summary of product characteristics (SmPC) of contraceptives containing desogestrel and etonogestrel.
This version
- Version
- 1 of 1
- Recorded
- October 03, 2026 20:37
- Change
- Initial
- Content hash
a1b42059edee6c8f652eafec9285ef4b- All versions
- Revision history